Anti-HER2 mAb, Trastuzumab, was clinically demonstrated to lead to a survival benefit in patients with HER2-overexpressing breast cancer (Slamon et al, 2001; Hall and Cameron, 2009). This evidence concerns the gene ERBB2 and breast carcinoma.